Zimacrol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zimacrol

What is Zimacrol?

Zimacrol is a prescription medication belonging to the macrolide class of antibiotics. It is primarily used to manage various bacterial infections by inhibiting the growth and replication of susceptible microorganisms.

Mechanism of Action

The active component in Zimacrol works by interfering with the protein synthesis of bacteria. By binding to the 50S subunit of the bacterial ribosome, it prevents the assembly of essential proteins, which effectively halts the spread of the infection and allows the body's immune system to clear the remaining bacteria.

Common Applications

Zimacrol is typically utilized for the treatment of mild-to-moderate infections localized in different parts of the body, including:

  • Respiratory Tract Infections: Such as community-acquired pneumonia, acute worsening of chronic bronchitis, and sinus infections.
  • Throat and Tonsil Infections: Including pharyngitis and tonsillitis caused by specific bacterial strains.
  • Skin and Soft Tissue Infections: Managing uncomplicated infections of the skin structure.
  • Urogenital Infections: Addressing certain sexually transmitted bacterial conditions.

Characteristics

Unlike earlier generations of antibiotics, Zimacrol is characterized by its ability to maintain high concentrations within tissues over an extended period. This pharmacological profile often allows for shorter treatment durations compared to other antimicrobial therapies. It is important to note that as an antibiotic, Zimacrol is only effective against bacterial pathogens and does not treat viral infections such as the common cold or influenza.

Regulatory References

  1. Azithromycin: MedlinePlus Drug Information
  2. Azithromycin StatPearls

What side effects are possible with Zimacrol?

Possible Side Effects and Safety Information

The safety profile of Zimacrol (Azithromycin) is officially categorized by regulatory agencies based on the frequency and type of documented adverse reactions. The most common effects often involve the Gastrointestinal System, including diarrhea, nausea, vomiting, and abdominal pain. Headaches are also listed as common.

Less frequent, but clinically significant, serious adverse reactions are documented across several organ systems. The label specifies risks involving the Hepatobiliary System, including rare reports of severe hepatotoxicity, hepatic necrosis, and liver failure. Serious reactions also extend to the Cardiac System, where the drug is officially associated with QT interval prolongation and the risk of Torsades de Pointes, a rare but potentially fatal arrhythmia.

Regulatory documents highlight several severe Immunological and Dermatological reactions, such as anaphylaxis and life-threatening conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These are typically classified as having an unknown frequency (post-marketing reports).

Safety notes for specific populations are also included in official labeling. Older adults may have an increased susceptibility to the documented proarrhythmic effects. For neonates (up to 42 days old), the use of this antibiotic carries an official risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). The safety profile is further defined by contraindications, which include known hypersensitivity to any macrolide antibiotic or a prior history of cholestatic jaundice associated with Azithromycin use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Zimacrol (Azithromycin) is officially defined by the exaggeration of known gastrointestinal symptoms. The documented manifestations upon overexposure may include severe nausea, vomiting, diarrhea, stomach discomfort, and abdominal pain.

The most critical regulatory concern involves the cardiovascular system. High concentrations are documented to carry a risk of prolongation of the QT interval, an electrical abnormality that can escalate to the life-threatening rhythm known as Torsades de pointes or other cardiac arrhythmias. Due to this severe outcome risk, hospital monitoring and a prolonged period of observation are typically required.

Immediate Emergency Action

Immediate medical attention is mandated for any suspected overdose. Seek immediate medical attention for symptoms such as an irregular heartbeat, shortness of breath, dizziness, or fainting. Authorities require contacting emergency services if the person has collapsed, experienced a seizure, or cannot be awakened.

Management Protocol

Regulatory labels state that no specific antidote is known for Azithromycin overdose. Management must therefore be symptomatic and supportive. Procedural measures described in the official prescribing information include the potential administration of medicinal charcoal and the provision of general supportive care to stabilize the patient's condition.

Therapeutic Uses of Zimacrol

Zimacrol is applied in addressing infections caused by susceptible bacteria and provides support that helps ease the overall symptom burden across several therapeutic domains. The medication is commonly used across conditions presenting with acute episodes in therapeutic areas like the respiratory system, ears, skin, and reproductive tract. This medication contributes to easing the overall symptom load and supports general well-being during symptomatic phases.


Alleviating Acute Symptoms

This medication is generally used to help with conditions characterized by periods of heightened symptoms in the respiratory and ENT tracts, such as community-acquired pneumonia, bronchitis exacerbations, sinusitis, and acute otitis media. It assists in managing symptom clusters that may become intense or disruptive, including fever, persistent cough, and localized pain. This use supports the patient during difficult episodes by easing distress.


Supporting Management Across Key Domains

Zimacrol is relevant for easing symptoms related to inflammatory or irritative states in skin and soft tissue infections. It is also relevant in contexts marked by increased discomfort or tension in the genital tract, including cervicitis and urethritis.

Quick Fact: Supports Management of Symptoms that Interfere with Daily Functioning


The drug may be part of symptomatic management in situations where alternative treatments are needed, which is considered relevant for patient groups with specific sensitivities. It is also relevant in contexts involving heightened systemic burden for specific infections in at-risk patient groups. This supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zimacrol — Official Regulatory Information

This map summarizes the official population eligibility rules for Zimacrol (Azithromycin), based strictly on government-approved prescribing information (FDA, EMA/SmPC).


Eligibility Scope

Category Eligibility Statement (Strictly Label-Based) Regulatory Basis
Populations for whom use is allowed Adults and adolescents ge 16 years of age. Pediatric patients ge 6 months of age for certain uses, like acute otitis media. FDA / EMA
Populations for whom use is not recommended Patients with pneumonia who are inappropriate for oral therapy due to moderate to severe illness or risk factors. FDA
Populations for whom use is contraindicated Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or any ketolide drug. Patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use. FDA / EMA

Age-Related Eligibility Rules

  • Infants (under 6 months): Safety and effectiveness in the treatment of patients under 6 months of age have not been established for many indications.
  • Neonates (up to 42 days): Use has been associated with reports of Infantile Hypertrophic Pyloric Stenosis (IHPS).
  • Older Adults (Geriatric): Elderly patients may be more susceptible to the development of torsades de pointes arrhythmias.

Condition-Specific Eligibility Rules

  • Cardiovascular Conditions: Use should be considered with caution in patients with pre-existing QT prolongation, a history of torsades de pointes, or other proarrhythmic conditions.
  • Neuromuscular Conditions: May exacerbate muscle weakness in persons with Myasthenia Gravis.
  • Hepatic Impairment: Caution is warranted in patients with impaired hepatic function. Contraindicated in patients with a history of azithromycin-associated hepatic dysfunction.

Pregnancy and Lactation Eligibility Status

  • Pregnancy: Should be used during pregnancy only if clearly needed and the benefit outweighs the potential risk.
  • Lactation/Breastfeeding: Azithromycin is present in human milk. A decision must be made whether to discontinue nursing or discontinue the drug.

Connection to the overall eligibility profile: Regulatory documents define eligibility for Zimacrol by establishing absolute contraindications (allergy, prior liver injury) and issuing severe Warnings and Precautions for use in specific populations (cardiac risk, myasthenia gravis, severe hepatic impairment). Age restrictions are defined by specifying a minimum age for established use and noting a developmental risk (IHPS) in neonates. The official labeling thus precisely delineates who may use the medicine and under what documented conditions or exclusions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Zimacrol (Azithromycin) is structured around mandatory restrictions, required monitoring, and specific administration rules documented by regulatory authorities.


Interaction Scope

Property Value
Medicinal product categories with documented interactions Drugs that prolong the QT interval, oral anticoagulants, HIV protease inhibitors, immunosuppressants, antacids.
Specific interacting medicines (if explicitly listed) Ergot Derivatives, Pimozide, Nelfinavir, Digoxin, Ciclosporin, Warfarin, Aluminum/Magnesium-containing Antacids.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic (PK) interaction (e.g., increased serum concentrations of Azithromycin by Nelfinavir; altered Cmax by Antacids; increased exposure of P-gp substrates). Pharmacodynamic (PD) interaction (additive QT prolongation risk). Lack of significant interaction with the hepatic Cytochrome P450 system.

Interaction Classifications (High-Level)

Property Value
Interaction severity classification (as defined in official documents) Contraindicated (e.g., Ergot Derivatives, Pimozide); Use with Caution/Monitoring Required (e.g., Warfarin, Digoxin, QT-prolonging drugs).

Official Interaction Statements

Co-administration with Ergot Derivatives and Pimozide is formally contraindicated by regulatory bodies. Azithromycin does not interact significantly with the hepatic Cytochrome P450 system. However, it can increase the plasma concentrations of certain P-glycoprotein (P-gp) substrates like Digoxin and Ciclosporin, necessitating patient monitoring. The use of Azithromycin with other QT-prolonging drugs significantly increases the documented risk of cardiac arrhythmias. Administration with Aluminum/Magnesium-containing Antacids requires a mandated time separation to prevent a reduction in the drug's peak concentration (Cmax). The official labeling notes that the risk of interaction severity is explicitly heightened in patients with significant hepatic disease.

Mechanism of Action

Targeting Bacterial Protein Synthesis

The core function of Zimacrol is to interfere with the fundamental machinery required for bacterial replication. The molecule reversibly binds to the 23S rRNA component of the bacterial 50S ribosomal subunit, physically blocking the process of translocation. This mechanism functions as a protein synthesis inhibitor, causing the premature cessation of polypeptide chain elongation and leading directly to the arrest of bacterial growth (bacteriostasis) at the cellular level.


️ Modulating Local Inflammatory Pathways

Beyond its direct antibacterial action, Zimacrol is associated with a secondary mechanism that influences the host immune response. The drug modulates specific host cell signaling, which decreases the release of certain pro-inflammatory mediators like IL-8. This action contributes to decreasing the activity of pro-inflammatory mediators at the tissue level, contributing to the overall physiological effect profile of the drug.


Addressing Mechanistic Evasion

The functionality of the drug's mechanism is physiologically constrained by bacterial defense strategies, primarily involving target modification and active removal. If the bacteria's 23S rRNA binding site is modified (e.g., via erm gene methylation) or if efflux pumps actively expel the drug, the necessary inhibitory concentration cannot be maintained, thus neutralizing the drug's mechanism of action.

Dosage and Administration Information

How Zimacrol (Azithromycin) is Used: Official Administration Guidelines

Zimacrol is administered according to standardized, high-level regimens detailed in official documents. Its long half-life supports a once-daily frequency, which is characteristic of its usage pattern across various infections. The medicine is primarily available for the oral route of administration in the form of tablets, capsules, and suspensions. However, an Intravenous (IV) Infusion route is officially established for the initial treatment of more severe conditions, such as Community-Acquired Pneumonia, before transitioning to oral therapy.


Administration Scope

Entity Instruction
Dosing schedule Most commonly a 3-day course (500 mg once daily) or a 5-day course (500 mg Day 1, then 250 mg Days 2–5). A single dose of 1 gram or 2 grams is used for specific infections.
Timing in relation to meals Oral tablets and standard suspensions can generally be taken with or without food. Certain extended-release oral formulations may require administration on an empty stomach (e.g., 1 hour before or 2 hours after a meal).
Preparation requirements The IV powder for injection must be reconstituted and diluted prior to administration. Oral suspensions require thorough shaking before use.
Special procedural conditions IV doses must be administered as a slow infusion over a period of 1 to 3 hours; they are not given as a rapid injection. Oral doses must be taken at least 1 hour before or 2 hours after taking antacids containing aluminum or magnesium due to absorption concerns.
Population-Specific Usage No general dose adjustment is required for older adult patients, or for those with mild to moderate renal or hepatic impairment. Pediatric dosing is precisely calculated on a weight-based (mg/kg) regimen.

Connection to the Official Use Protocol

The usage protocol is defined by short, fixed-duration courses and the required once-daily frequency, which simplifies the administration schedule. This structure, explicitly documented by health agencies, dictates precise dosage amounts, the necessary timing relative to other products like antacids, and the required slow administration technique for the IV formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zimacrol

Evidence for use in Respiratory Tract Infections: Pneumonia and Bronchitis

Research exploring Zimacrol's use in Community-Acquired Pneumonia (CAP) has relied on short-term Randomized Controlled Trials (RCTs) and large observational cohort studies conducted during periods of increased symptom activity. These studies monitored outcomes related to functional imbalance, such as outcomes monitoring physiological strain or stress over defined time intervals, the length of hospital stay, and measurements of outcomes related to clinical response in hospitalized and older adult patients.

Studies reported measurements of outcomes related to clinical response across various treatment regimens, often comparing Zimacrol-containing regimens against other antibiotics. Research also included monitoring of outcomes monitoring physiological strain or stress (e.g., 90-day post-treatment) in relevant trials.

For Acute Exacerbation of Chronic Bronchitis (AECB), studies explored short-term symptom changes, focusing on exacerbation frequency and outcomes related to systemic or functional imbalance. Findings describe patterns observed in these studies, reporting measurements of outcomes capturing phases of heightened symptom activity after short-term treatment.

Comparative evidence is lacking against all currently accepted alternative therapies, and the optimal duration of treatment is an area where data are still emerging. Long-term functional outcomes are not well characterized, and research requires ongoing monitoring regarding the potential for antimicrobial resistance selection.


Evidence for use in Urethritis and Cervicitis

Research for specific genital tract infections has been evaluated in Randomized Controlled Trials (RCTs) focusing on outcomes related to inflammatory or irritative states—the absence of the targeted pathogen—in adult men and women. Studies monitored measurements of outcomes related to inflammatory or irritative states determined by follow-up testing after defined time intervals.

However, data for certain groups remain insufficient, and long-term epidemiological surveillance is continually required to track the effectiveness of current regimens against evolving antimicrobial resistance. Subgroup findings are uncertain due to documented variability in outcomes.


What is Still Uncertain About Zimacrol Evidence

Evidence highlights what is known and what is still uncertain about Zimacrol. Comparative evidence is lacking for many alternative antibiotic regimens, and the long-term effects are not fully established regarding the potential for resistance selection. Research provides context but not individual predictions regarding long-term outcomes, and results apply only to the populations studied in the official regulatory trials.

Frequently Asked Questions (FAQ)

Common questions about Zimacrol (FAQ)


Q: Why is Zimacrol prescribed instead of other common medicines?

Official documents describe Azithromycin as an azalide, which is chemically distinct from other macrolides. This structure allows the drug to have a long half-life, meaning it stays in the body's tissues for an extended period. This extended tissue presence is the reason it is often used in shorter treatment courses compared to some older antibiotic therapies.


Q: What is Zimacrol used for besides the main condition?

The medicine is officially indicated for a variety of bacterial infections caused by susceptible organisms. These uses include treating respiratory tract infections like community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. It is also approved for certain skin structure infections and sexually transmitted infections (STIs).


Q: Does Zimacrol cause drowsiness or fatigue?

Official product information lists headache and dizziness among the commonly reported side effects. While drowsiness is not typically listed as a common effect, fatigue is reported in some official sources as an uncommon or rare side effect.


Q: What are the major foods or drinks that interact with Zimacrol?

For the oral tablets and standard suspension forms of Zimacrol, official instructions state that the medicine can generally be taken with or without food. Some patient information based on regulatory data indicates that consuming alcohol is usually permitted, but it may have the potential to worsen side effects like dizziness.


Q: Does Zimacrol interact with common over-the-counter pain relievers?

Regulatory documents provide specific warnings about interactions with certain prescription medicines and classes of drugs, such as blood thinners. The official drug interaction sections do not typically list common over-the-counter pain relievers as requiring a mandated warning or contraindication.


Q: Are there any specific supplements or vitamins that should be avoided while taking Zimacrol?

Official drug interaction information primarily focuses on potential issues with other prescription medicines. The core regulatory documents do not contain specific warnings or mandates to avoid common vitamins or supplements while using this medicine.


Q: Can Zimacrol affect birth control pills?

Regulatory labeling does not suggest that Azithromycin significantly alters the liver enzyme system responsible for metabolizing oral contraceptives. However, some sources based on regulatory data acknowledge that a potential risk of interaction with hormonal contraceptives is noted, and users are directed to refer to the guidance in their prescribing information.


Q: Is Zimacrol known to interact with medicines for high blood pressure?

Official warnings highlight an increased risk of specific heart rhythm changes, known as QT prolongation, when Zimacrol is taken with other medicines that also carry this risk. This group of drugs may include certain heart or blood pressure medicines. The regulatory documents mandate caution and monitoring for such use.


Q: What kind of liver monitoring is typically needed when using Zimacrol?

Official labeling states that caution is warranted when the drug is used by patients with impaired hepatic (liver) function. The product information states that immediate care should be sought if specific signs of liver injury develop, such as jaundice or severe abdominal pain.


Q: Do I need to avoid sun exposure while taking Zimacrol?

Increased sensitivity to sunlight, known as photosensitivity, is documented as a potential adverse effect of Azithromycin. For this reason, official patient information frequently references the need for sun protection measures to limit exposure to direct sunlight or tanning beds.


Q: Can Zimacrol change the taste of food?

Changes to the sense of taste, medically known as dysgeusia, are officially listed as a documented side effect of Azithromycin. While this is not considered a common event, it has been reported in regulatory documents.


Q: What should I do if I experience a rare side effect mentioned in the leaflet?

Official FDA safety communications state that immediate medical attention should be sought if patients experience severe, rare symptoms. This includes an irregular heartbeat, sudden shortness of breath, significant dizziness, or fainting.


Q: What are the most common reasons a doctor might choose Zimacrol?

The official indications for the drug are for treating infections that are caused by bacteria confirmed to be susceptible to Azithromycin. The medicine is commonly used for infections affecting the respiratory system and certain sexually transmitted infections.


Q: Is Zimacrol available in different strengths?

Yes, the active ingredient Azithromycin is officially available in multiple strengths to accommodate different treatment regimens. For example, it is supplied in different strengths for oral tablets (such as 250 mg and 500 mg) and various concentrations for oral suspensions.


Q: Are there any known interactions between Zimacrol and alcohol?

General patient guidance in some jurisdictions states that consumption of alcohol is not formally restricted while taking Azithromycin. However, it is noted that alcohol may potentially worsen common side effects of the medicine, such as dizziness.


Q: Is Zimacrol generally well-tolerated?

Based on clinical trial data summarized in regulatory documentation, Azithromycin is often described as generally well-tolerated. The most frequently reported adverse effects tend to be mild to moderate issues primarily affecting the gastrointestinal system.


Q: If I miss a dose, what is the generally accepted advice (non-personalized)?

General regulatory guidance is provided for a missed dose. The guidance typically directs taking the missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, the guidance is to skip the missed dose and resume the regular schedule. The guidance states that double or extra doses must not be taken.


Q: Can Zimacrol be crushed or split?

Official administration guidelines depend on the specific formulation being used. While some official sources permit crushing or dispersing the tablets in liquid or soft food, certain specialized or modified-release tablets—according to regulatory guidelines—must not be crushed or split to maintain their intended effects.


Q: Does Zimacrol affect blood sugar levels?

Regulatory documents do not typically list changes in blood sugar as a common side effect of Azithromycin. No specific warnings or contraindications regarding the use of the medicine in diabetic patients are commonly noted in the core labeling.


Q: Is Zimacrol considered a first-line or second-line treatment option?

Official documents sometimes classify Azithromycin as an alternative therapy for certain conditions, such as pharyngitis or tonsillitis. This use is often reserved for individuals who are not able to use or tolerate first-line treatments due to allergies or other factors.


Q: What is the official safety classification of Zimacrol?

Azithromycin does not have a single, simple overall safety tier. Its safety profile is described in detail through specific warnings and precautions outlined by regulatory bodies, including risks related to the cardiovascular system, hepatic function, and hypersensitivity reactions.


Q: Are there specific symptoms that warrant immediate medical attention while on Zimacrol?

Yes, regulatory guidance describes the need to seek immediate medical care if you notice certain severe symptoms while using Zimacrol. These include signs of a serious cardiac event (like an irregular heartbeat or fainting) or a severe allergic reaction (such as swelling of the face or throat).

How should Zimacrol be stored and disposed of?

How to Store and Dispose of Zimacrol?

The official storage requirements for Zimacrol (azithromycin) are defined by the specific formulation to maintain product stability and potency.


Storage Conditions

Formulation Temperature Requirement Additional Handling
Tablets / Unmixed Powder Controlled Room Temperature (20°C to 25°C) Must be protected from excessive heat and moisture.
Constituted Suspension Store at or below 30°C (86°F) Must not be frozen.

All forms must be stored in the original container, kept tightly closed, and maintained out of the sight and reach of children.

Disposal Instructions

The constituted oral suspension has a maximum use period of 10 days from the time of mixing; any portion remaining after this stability window must be discarded.

Unused or expired Zimacrol should not be placed in household waste or wastewater and must be disposed of according to local regulations for unwanted medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zimacrol found in:

A-Z Index: